Skip to navigation Skip to content

X-linked hypophosphataemia (XLH) Program in Pharmaceutical Benefits Scheme (PBS) 012-22102650

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised burosumab for patients with X-linked hypophosphataemia (XLH).

XLH and listing dates

XLH is an inherited rare condition that affects bones, muscles, and teeth due to the excessive loss of phosphate.

Listing dates:

  • burosumab - 1 November 2022

See Written Authority Required Drugs, for more information.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • contact details
  • item and restriction codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)